Skip to main content
SpringerLink
Log in

Prevalence of hormone receptors and HER2/neu in breast cancer cases in Jordan

  • Article
  • Published:
Pathology & Oncology Research

Abstract

The management and prognosis of breast cancer nowadays require the evaluation of Estrogen (ER), Progesterone Receptors (PR) and HER2/neu. Ethnic variation in the expression of these receptors is well documented. The aim of this study is to determine the prevalence of ER, PR and HER2/neu among Jordanian women with breast cancer of ductal and lobular types. A retrospective analysis was performed on 267 cases of breast cancer referred for treatment at King Hussein Cancer Center, Jordan between the period of June 2003 and June 2004. Standard immune stains were used for evaluation of hormone receptors and HER2/neu. In addition, evaluation of HER2/neu was done by FISH in selected cases. Of these 267 cases, 240 (89.9%) were ductal carcinomas of various histological grades, 122 (50.8%) of which were ER-positive, 138 (57.5%) PR-positive and 42 (17.5%) HER2/neu-positive. Twentytwo (8.2%) of all cases were lobular carcinomas, 15 (68%) of which were ER-positive,20 (90.9%) PR-positive and 3 (13.6%) HER2/neu-positive. Five (1.9%) of the total cases were of mixed lobular and ductal types, 4 (80%) of which were ER-positive, 3 (60%) PR-positive and none were positive for HER2/neu. The prevalence of hormone receptor positivity in breast cancer of Jordanian women is lower than that of the western populations and close to other populations such as the Chinese and the minor ethnic groups of Northern America (African Americans).(Pathology Oncology Research Vol 12, No 2, 83–86)

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Reference

  1. Lazennec G, Bresson D, Lucas A, et al: ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology 142: 4120–4130, 2001

    Article  PubMed  CAS  Google Scholar 

  2. Anderson E, Clarke RB, Howell A: Estrogen responsiveness and control of normal human breast proliferation. Review. J Mammary Gland Biol Neoplasia 3: 23–35, 1998

    Article  CAS  Google Scholar 

  3. Osborne CK, Yochmowitz MG, Knight WA 3rd,McGuire WL: The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46: 2884–2888, 1980

    Article  PubMed  CAS  Google Scholar 

  4. Wittliff JL: Steroid-hormone receptors in breast cancer. Cancer 53 (3 Suppl): 630–643, 1984

    Article  PubMed  CAS  Google Scholar 

  5. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: correlation of relapse and survival with amplification of the HER- 2/neu oncogene. Science 235: 177–182, 1987

    Article  PubMed  CAS  Google Scholar 

  6. Shak S: Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Review. Semin Oncol 4 Suppl12: 71–77, 1999

    Google Scholar 

  7. Cobleigh MA, Vogel CL, Tripathy D, et al: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 9: 2639–2648, 1999

    Google Scholar 

  8. Tavassoli FA, Devilee P (Eds.): World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. IARC Press: Lyon, 2003

    Google Scholar 

  9. Pegoraro RJ, Karnan V, Nirmul D, Joubert SM: Estrogen and progesterone receptors in breast cancer among women of different racial groups. Cancer Res 46: 2117–2120, 1986

    PubMed  CAS  Google Scholar 

  10. Ruder AM, Lubin F, Wax Y, et al: Estrogen and progesterone receptors in breast cancer patients. Epidemiologic characteristics and survival differences. Cancer 64: 196–202, 1989

    Article  PubMed  CAS  Google Scholar 

  11. Gapstur SM, Dupuis J, Gann P, et al: Hormone receptor status of breast tumors in black, Hispanic, and non-Hispanic white women. An analysis of 13,239 cases. Cancer 77: 1465–71, 1996

    Article  PubMed  CAS  Google Scholar 

  12. Joslyn SA: Hormone receptors in breast cancer: racial differences in distribution and survival. Breast Cancer Res Treat 73: 45–59, 2002

    Article  PubMed  CAS  Google Scholar 

  13. Li CI, Malone KE, Daling JR: Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. Cancer Epidemiol Biomarkers Prev 7: 601–607, 2002

    Google Scholar 

  14. Chu KC, Anderson WF, Fritz A, et al: Frequency distributions of breast cancer characteristics classified by estrogen receptor and progesterone receptor status for eight racial/ethnic groups. Cancer 92: 37–45, 2001

    Article  PubMed  CAS  Google Scholar 

  15. Stierer M, Rosen H, Weber R, et al: Immunohistochemical and biochemical measurement of estrogen and progesterone receptors in primary breast cancer. Correlation of histopathology and prognostic factors. Ann Surg 218: 13–21, 1993

    Article  PubMed  CAS  Google Scholar 

  16. Chow LW, Ho P: Hormonal receptor determination of 1,052 Chinese breast cancers. J Surg Oncol 75: 172–175, 2000

    Article  PubMed  CAS  Google Scholar 

  17. Lertsanguansinchai P, Chottetanaprasith T, Chatamra K, et al: Estrogen and progesterone receptors status in Thai female breast cancer patients: an analysis of 399 cases at King Chulalongkorn Memorial Hospital. J Med Assoc Thai 85, Suppl 1: S193–202, 2002

    PubMed  Google Scholar 

  18. Ikpatt OF, Ndoma-Egba R: Oestrogen and progesterone receptors in Nigerian breast cancer: relationship to tumour histopathology and survival of patients. Cent Afr J Med 49: 122–126, 2003

    PubMed  CAS  Google Scholar 

  19. Al-Alwan NA, Al-Kubaisy W, Al-Rawaq K: Assessment of response to tamoxifen among Iraqi patients with advanced breast cancer. East Mediterr Health J 6: 475–82, 2000

    PubMed  CAS  Google Scholar 

  20. Abadjian G, Antoun R: Breast carcinoma: evaluation of hormone receptors and pS2, erb-B2, P-glycoprotein and Ki-67 markers. J Med Liban 44: 10–15. 1996 in French

    PubMed  CAS  Google Scholar 

  21. Samir S Amr, Abdul Rahman M. Sa’di, Fazal Ilahi, et al: Spectrum of Breast Diseases In Saudi Arab Females: A 26 Year Pathological Survey At Dhahran Health Center. Ann Saudi Med 15: 125–132, 1995

    PubMed  CAS  Google Scholar 

  22. McCarthy NJ, Yang X, Linnoila IR, et al: Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer. Clin Cancer Res 8: 3857–3862, 2002

    PubMed  CAS  Google Scholar 

  23. Arpino G, Bardou VJ, Clark GM, Elledge RM: Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res 6: 149–156, 2004

    Article  Google Scholar 

  24. Ross JS, Fletcher JA: HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol 112(Suppl 1): S53–67, 1999

    PubMed  CAS  Google Scholar 

  25. Ameyaw MM, Tayeb M, Thornton N, et al: Ethnic variation in the HER-2 codon 655 genetic polymorphism previously associated with breast cancer. J Hum Genet 47: 172–175, 2002

    Article  PubMed  CAS  Google Scholar 

  26. Sellami M, Gamoudi M, Krichen K, et al: Incidence of amplification of the C-erb B2/Her-2/neu gene in human breast cancer (in French). Arch Inst Pasteur Tunis 68: 33–41, 1991

    PubMed  CAS  Google Scholar 

  27. El-A Helal T, Khalifa A, Kamel AS: Immunohistochemical expression of p53 and c-erbB2 proteins in breast cancer in Egypt. Anticancer Res 20: 2145–2150, 2000

    Google Scholar 

  28. Middleton LP, Palacios DM, Bryant BR, Krebs P, Otis CN, Merino MJ: Pleomorphic lobular carcinoma: morphology, immunohistochemistry, and molecular analysis. Am J Surg Pathol 24: 1650–1656, 2000

    Article  PubMed  CAS  Google Scholar 

  29. Feuer EJ, Wun LM: DEVCAN: Probability of Developing or Dying of Cancer. Version 4.0. Bethesda MD: National Cancer Institute. 1999.

    Google Scholar 

  30. Al-Kayed S, Al-Hijawi B, Al-Haliq T: Incidence of cancer in Jordan 2001. National Cancer Registry, Ministry of Health/Jordan, 2001

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, King Hussein Cancer Center, Queen Rania AlAbdullah Str., P.O. Box: 1269, 11941, Amman, Jordan

    Maher A. Sughayer MD & Maha M. Al-Khawaja

  2. Department of Medical Oncology, King Hussein Cancer Center, Amman, Jordan

    Suleiman Massarweh

  3. Department of Surgical Oncology, King Hussein Cancer Center, Amman, Jordan

    Mahmoud Al-Masri

Authors
  1. Maher A. Sughayer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maha M. Al-Khawaja
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Suleiman Massarweh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mahmoud Al-Masri
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sughayer, M.A., Al-Khawaja, M.M., Massarweh, S. et al. Prevalence of hormone receptors and HER2/neu in breast cancer cases in Jordan. Pathol. Oncol. Res. 12, 83–86 (2006). https://doi.org/10.1007/BF02893449

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02893449

Key words

Search

Navigation